Heparanase expression in human colorectal cancer and its relationship to tumor angiogenesis, hematogenous metastasis, and prognosis

Journal of Surgical Oncology

Volumn 87, Issue 4, 2004, Pages 174-181

  Sato, Tomohiro ^a   Yamaguchi, Akio ^a   Goi, Takanori ^a   Hirono, Yasuo ^a   Takeuchi, Kazuo ^a   Katayama, Kanji ^a   Matsukawa, Shigeru ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

Angiogenesis; Colorectal cancer; Hematogenous metastasis; Heparanase; Tumor invasion

Indexed keywords

CD34 ANTIGEN; HEPARANASE; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD34; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; COX REGRESSION MODEL; GENE OVEREXPRESSION; HEMATOGENOUS METASTASIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; SEROSA; SEROSA INVASION; STATISTICAL ANALYSIS; STATISTICAL MODEL; TUMOR VASCULARIZATION; VEIN; VEIN INVASION;

CELL LINE, TUMOR; COLORECTAL NEOPLASMS; GLUCURONIDASE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; HUMANS; LIVER NEOPLASMS; MULTIVARIATE ANALYSIS; NEOPLASM CIRCULATING CELLS; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PERITONEAL NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE;

EID: 4444323613     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.20097     Document Type: Article

References (27)

1. Goshen R, Hochberg AA, Korner G, et al.: Purification and characterization of placenta heparanase and its expression by cultured cytotrophoblasts. Mol Hum Reprod 1996;2:679-684.
2. Oosta GM, Favreau LV, Beeler DL, et al.: Purification and properties of human platelet heparanase. J Biol Chem 1982;257:11249-11255.
3. Freeman C, Parish CR: Human platelet heparanase: Purification, characterization, and catalytic activity. Biochem J 1998;330:1341-1350.
4. Hoogewerf AJ, Leone JW, Reardon IM, et al.: CXC chemokines connective tissue activating peptide-III and neutrophil activating peptide-2 are heparin/heparan sulfate-degrading enzymes. J Biol Chem 1995;270:3268-3277.
5. Jin L, Nakajima M, Nicolson GL: Immunochemical localization of heparanase in mouse and human melanoma. Int J Cancer 1990;45:1090-1095.
6. Hulett MD, Freeman C, Hamdorf BJ, et al.: Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat Med 1999;5:803-809.
7. Vlodavsky I, Friedmann Y, Elkin M, et al.: Mammalian heparanase: Gene cloning, expression, and function in tumor progression and metastasis. Nat Med 1999:5:793-802.
8. Toyoshima MT, Nakajima M: Human haparanase. Purification, characterization, cloning, and expression. J Biol Chem 1999;274:24153-24160.
9. Kussie P, Hulmes JD, Ludwig DL, et al.: Cloning and functional expression of a human heparanase gene. Biochem Biophys Res Commun 1999;261:183-187.
10. Koliopanos A, Friess H, Kleeff J, et al. Heparanase expression in primary and metastaticpancreatic cancer. Cancer Res 2001;61:4655-4659.
11. Maxhimer JB, Quiros RM, Stewart R, et al.: Heparanase-1 expression is associated with the metastatic potential of breast cancer. Surgery 2002;132:326-333.
12. Kosir M, Quinn C, Zukowski K, et al.: Human prostate carcinoma cells produce extracellular heparanase. J Surg Res 1997;67:98-105.
13. Goldshmidt O, Zcharia E, Abramovitch R, et al.: Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis. PNAS 2002;99:10031-10036.
14. Ishai-Michaeli R, Eldor A, Vlodavsky I: Heparanase activity expressed by platelets, neutrophils, and lymphoma cells, releases active fibroblast growth factor from extracellular matrix. Cell Regul 1990;1:833-842.
15. Faham S, Hileman RE, Fromm JR, et al.: Heparin structure and interactions with basic fibroblast growth factor. Science 1996;271:1116-1120.
16. Park JE, Keller GA, Ferrara N: The vascular endothelial growth factor (VGEF) isoform: Differential deposition into the subepitherial extra cellular matrix and bioactivity of extracellular matrix bound VEGF. Mol Biol Cell 1993:4:1317-1326.
17. Raines EW, Ross R: Compartmentalization of PDGF on extracellular binding sites dependent on exon-6-encoded sequences. J Cell Biol 1992;116:533-543.
18. Eccles SA. Heparanase: Breaking down barriers in tumors. Nat Med 1999;5:735-736.
19. Vlodavsky I, Eldor A, Haimovitz-Friedman A, et al.: Expression of heparanase by platelets and circulating cells of the immune system: Possible involvement in diapedesis and extravasation. Invasion Metastasis 1992;12:112-127.
20. Fleming ID, Cooper JS, Henson DE, et al.: AJCC cancer staging manual, 5th edn. Philadelphia: Lippincott-Raven, 1997.
21. Japanese Research Society for Cancer of the Colon and Rectum: Japanese classification of colorectal carcinoma. Tokyo: Kanehara, 1997.
22. Cox DR: Regression models and life tables. JR Stat Soc 1972;34B:187-220.
23. Kleinbaum DG, Kupper LL, Mogenstern H: Epidemiologic research: Principles and quantitative models. New York: Van Nostrand Reinhold Company, 1982. pp 87-99.
24. El-Assal ON, Yamanoi A, Ono T, et al.: The clinicopathological significance of heparanase and basic fibroblast growth factor expression in hepatocellular carcinoma. Clin Cancer Res 2001;7:1299-1305.
25. Inoue H, Mimori K, Utsnomiya T, et al.: Heparanase expression in clinical digestive malignancies. Oncol Rep 2001;8:539-542.
26. Friedmann Y, Vlodavsky I, Aingorn H, et al.: Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis. Am J Pathol 2000;157:1167-1175.
27. Elkin M, Ilan N, Ishai-Michaeli R, et al.: Heparanase as mediator of angiogenesis: Mode of action. FASEB J 2001;15:1661-1663.